2020 First Transaction Completed

2020 First Transaction Completed

After a 2019 outstanding performance with 4 crossborder M&A transactions completed, there is no a better way to begin the 2020 with the announcement of our first transaction completed!

On January 3, 2020, Mr. Li, formally signed for the purchase of 500,000 newly issued Class A convertible preferred shares of CTI for US $5 million. The first $2.5 million is expected to be funded on or before January 10, 2020, while the balance of $2.5 million will close after certain conditions are met.

In addition, Mr. Li will appoint a new Director to the Board.

Once the transaction was announced, the stock skyrocketed, closing Monday, January 6, up 225%, from Friday’s, January 3, closing price. A record 22.9 million shares of the Company’s stock traded in one day.

Thanks to all the team members who made it possible.

 

Continue reading

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

HONG KONG, 18 June 2026 — ARC Group today announced that it has committed to invest in Cloudbreak Pharma Inc. (HKEX: 2592), a clinical-stage ophthalmology biotechnology company with operations across the United States and China, following the signing of a share subscription agreement through its wholly owned subsidiary ARC Group International Limited. The transaction marks […]
Rising Together | ARC Dragon Boat Team Takes to the Water
Bio Green Med Solution, Inc. Announces Business Combination Agreement to Acquire Future NRG Sdn. Bhd.
Inside ARC Group | University of Nottingham Ningbo China

Please complete this form to download the case study

This field is for validation purposes and should be left unchanged.
*Required before submission